Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: Assay development and application to pharmacokinetic and tissue distribution studies

Biomedical Chromatography

Volumn 29, Issue 5, 2015, Pages 679-688

  Chen, Xiao ^a   Wang, Zhong ^a   Liu, Mengping ^a   Liao, Min ^a   Wang, Xinfeng ^a   Du, Huajuan ^a   Chen, Jiefeng ^a   Yao, Meicun ^a   Li, Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Distribution; Mouse; Pharmacokinetics; Sunitinib; UPLC MS MS

Indexed keywords

ELECTROSPRAY IONIZATION; HISTOLOGY; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; METABOLITES; TISSUE;

ACTIVE METABOLITES; ASSAY DEVELOPMENT; DEVELOPMENT AND APPLICATIONS; DISTRIBUTION; MICE PLASMA; MOUSE; MOUSE TISSUES; SUNITINIB; TISSUE DISTRIBUTIONS; UPLC-MS/MS;

PHARMACOKINETICS;

N DEETHYLSUNITINIB; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; LIVER HOMOGENATE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; CHEMISTRY; EVALUATION STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LUNG; METABOLISM; PROCEDURES;

ANIMALIA; MUS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INDOLES; KIDNEY; LIVER; LUNG; MICE; PYRROLES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84927783795     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3331     Document Type: Article

References (22)

1. Adams VR and Leggas PM. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical Therapeutics 2007; 29: 1338-1353.
2. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal RM, Moore N, Titier K and Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultraperformance LC/MS-MS. Clinica Chimica Acta - International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine 2011; 412: 1060-1067.
3. Bruijn PD, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA and Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultraperformance liquid chromatography/tandem triple-quadrupole mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 934-941.
4. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Annals of Oncology 2007; 18: 3-10.
5. Erp NPV, Wit DD, Guchelaar HJ, Gelderblom H, Hessing TJ and Hartigh J. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 2013; 937: 33-43.
6. Gotze L, Hegele A, Metzelder SK, Renz H and Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clinica Chimica Acta - International Journal of Clinical Chemistry and Diagnostic Laboratory Medicine 2012; 413: 143-149.
7. Gradinaru J, Vullioud A, Eap CB and Ansermot N. Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 2014; 88: 36-44.
8. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L and Wu EY. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemotherapy and Pharmacology 2009; 64: 691-706.
9. Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ and Phelps MA. Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis 2014; 88: 262-268.
10. Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH and Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography 2013; 27: 466-476.
11. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annual Reviews: Pharmacology and Toxicology 2013; 53: 161-185.
12. Levitzki A and Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annual Review of Biochemistry 2006; 75: 93-109.
13. Minkin P, Zhao M, Chen Z, Ouwerkerk J, Gelderblom H and Baker SD. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 2008; 874: 84-88.
14. Oberoi RK, Mittapalli RK, Fisher J and Elmquist WF. Sunitinib LC-MS/MS assay in mouse plasma and brain tissue: application in cns distribution studies. Chromatographia 2013; 76: 23-24.
15. Qiu F, Bian W, Li J and Ge Z. Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. Biomedical Chromatography 2013; 27: 615-621.
16. Remko M, Boháč A and Kováčiková L. Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents. Structural Chemistry 2011; 22: 635-648.
17. Rodamer M, Elsinghorst PW, Kinzig M, Gutschow M and Sorgel F. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study. Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences 2011; 879: 695-706.
18. Schmidinger M and Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews 2010; 36: 416-424.
19. Sodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A and Johnson CD. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Critical Reviews in Oncology/Hematology 2014; 91: 35-46.
20. 14C]sunitinib in rats, monkeys, and humans. Drug Metabolism and Disposition 2012; 40: 539-555.
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. Guidance for Industry Bioanalytical Method Validation. Rockville, MD, 2001.
22. Zhou Q and Gallo JM. Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 958-964.